

Edgar Filing: SPECTRUMEDIX CORP - Form NT 10-K

SPECTRUMEDIX CORP
Form NT 10-K
July 02, 2001

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 12b-25

Commission File Number 000-09428

NOTIFICATION OF LATE FILING

(Check One): Form 10-K Form 11-K Form 20-F Form 10-Q

Form N-SAR
For Period Ended: March 31, 2001

 Transition Report on Form 10-K Transition Report on Form 10-Q
 Transition Report on Form 20-F Transition Report on Form N-SAR
 Transition Report on Form 11-K

For the Transition Period Ended: _____

Read attached instruction sheet before preparing form. Please print or type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify item(s) to which the notification relates: _____

1

Part I. Registrant Information

Full name of registrant SpectruMedix Corporation

Former name if applicable

Address of principal executive office (Street and number)
2124 Old Gatesburg Road

City, State and Zip Code State College, Pennsylvania 16803

Part II. Rule 12b-25(b) and (c)

If the subject report could not be filed without unreasonable effort or

Edgar Filing: SPECTRUMEDIX CORP - Form NT 10-K

expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check appropriate box.)

- (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
- (b) The subject annual report, semi-annual report, transition report on Form 10-K, 20-F, 11-K or Form N-SAR, or portion thereof will be filed on or before 15th calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

Part III. Narrative

State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR or the transition report portion thereof could not be filed within the prescribed time period. (Attach extra sheets if needed).

The Registrant's Annual Report on Form 10-K could not be filed within the proscribed time period because management was focused on certain business matters and management was unable to complete its review of the Registrant's financial statements.

Part IV. Other Information

(1) Name and telephone number of person to contact in regard to this notification.

Karl Fazler

(814) 867-8600

(Name)

(Area Code) (Telephone Number)

(2) Have all other periodic reports required under Sections 13 and 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

Yes No

2

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes No

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

For the year ended March 31, 2001, the Registrant will report revenues of \$3,783,057 as compared to revenues of \$1,193,405 for the year ended March 31, 2000. The revenues for fiscal year 2001 included over \$1,900,000 of sublicense and consulting fees generated from agreements entered into in July 1999 compared to approximately \$870,000 in 2000. Also, the Registrants sales for the 2001

Edgar Filing: SPECTRUMEDIX CORP - Form NT 10-K

fiscal year included the sale of seven of the Registrant's principal products compared to one in 2000.

SpectruMedix Corporation

(Name of registrant as specified in charter)

Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Date: July 2, 2001

By: /s/ Joseph K. Adlerstein

Name: Joseph K. Adlerstein

Title: President and Chief Executive Officer